Antibiotic resistance is one of the most pressing public health issues facing the world today. We helplessly witness nowadays the increase and spread of N.meningitidis strains with penicillin G decreased susceptibility and strains resistant to chloramphenicol appearance which causes therapeutic strikes and often death. After bacteriological identification from Gram staining, latex agglutination, culture and specific antisera agglutination, an antibiogram was performed with for clinical and carried N.meningitidis resistance profile study. A penicillin G E-Test was performed by using oxacillin and chloramphenicol carried strains resistant to confirm it profile resistance. The isolation of clinical and carried N.meningitidis strains was done on TMM agar, blood agar and/or chocolate agar +PVX and incubated at 37°C between 18 to 24 hours. This study was done at CHR of Kaya lab in Burkina Faso from 2016 to 2017.

Clinical strains diagnosis showed 22(2.6%) by Gram staining, 22(2.6%) by latex agglutination and 10 (1.2%) by Culture. Carried strains diagnosis showed 86.85% of non-groupable serogroups (NG), 12.54% NmW and 0.61% NmC. Clinical strains antibiogram showed 100% of sensitivity to Chloramphenicol, Ampicillin, Ceftriaxone and Augmentin. It showed also 90% of sensitivity against 10% resistance for Penicillin G and Oxacillin. Carried strains antibiogram showed 92.86% of sensitivity to chloramphenicol, 83.33% of sensitivity to oxacillin against 7.14% of resistance to chloramphenicol and 16.67% of resistance to oxacillin for groupables N.meningitidis. Non-groupable N.meningitidis antibiogram showed 92.79% of sensitive to chloramphenicol, 90.14% of sensitive to oxacillin against 7.21% of resistance to chloramphenicol and 9.86% of resistance to oxacillin. This study showed a significant decreased of penicillin G resistance and a high level of resistance to chloramphenicol among clinical and community N.meningitidis. Due to emergence of resistant clinical and community strains, it requires a good protocol treatment policy implementation to reduce N. meningitidis outbreak in developing country.

Dr. Emmanuel Sampo was born on December 31, 1969, in Ouagadougou, Burkina Faso. He currently resides in Ouagadougou. He holds a PhD degree awarded in December 2024 from Joseph Ki-Zerbo University. His doctoral research focused on “Molecular characterization and antibiotic resistance of Neisseria meningitidis carriage in the health districts of Kaya and Boussouma in Burkina Faso.” In relation to his professional training, Dr. Sampo completed biomedical technologist programs at the National Public Health School of Ouagadougou during two periods: from 2000 to 2003 and again from 2009 to September 2010.